Press Releases Search Search Category Topic Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Institute & Campus (1) Press release (88) (-) Science (8) Animal Research (7) Art (1) Artificial Intelligence (4) Basic Research (2) BIH (2) BIMSB (3) Biochemistry & Proteomics (2) Campus (1) Campus Buch (1) (-) Cancer (5) Cardiovascular Research (7) Cell Biology (5) Charité (3) Clinical Research (1) Computational Biology (2) CRISPR/Cas9 (4) Data science (1) Developmental Biology (3) Disease-related Research (5) DZHK (3) ECRC (1) ERC (1) EU-Life (1) FMP (1) Gene Expression Regulation & RNA Biology (2) Genetics & Genomics (7) High-throughput technologies (1) History (1) Imaging (3) (-) Immunology (3) Immunotherapy (1) LifeTime (4) MDC-Forschung (1) NAKO (1) Neuroscience (3) OpenScience (3) Organoids (4) Personalia (3) Research Highlight (10) Responsible Research (1) Single-cell analysis (10) Stem Cell Biology (7) Systems Biology (4) Teachers & Pupils (1) Technology Platforms (1) Technology Transfer (1) Women in Science (1) Work and Family (1) 8 Results: Active Filter: ScienceCancerImmunology Sort: Result score Newest to oldest Oldest to newest Press Release No. 20 May 13, 2019 Berlin Why Hodgkin’s lymphoma cells grow uncontrollably Although classical Hodgkin’s lymphoma is generally easily treatable today, many aspects of the disease still remain a mystery. A team at the MDC led by Professor Claus Scheidereit has now identified an important signaling molecule in the biology of this lymphoma: LTA. Press Release No. 18 May 03, 2019 Berlin First “wave” of the German National Cohort is completed In late April, the Berlin-North study center at the MDC welcomed its 10,000th subject in the GNC health study. This completes the first round of baseline examinations. Press Release No. 4 February 14, 2019 Berlin On the origin of B1 cells A new MDC study may resolve a decades-old debate in immunology: A team led by Prof. Klaus Rajewsky reports in Science that distinct progenitor cells are not required for the development of B1 cells. Instead, the team’s experiments show that a particular type of B-cell receptor can reprogram B2 cells into B1 cells, suggesting that B1 cells emerge as a consequence of their special B-cell receptors. Press Release No. 20 September 04, 2018 Berlin The brain’s tiny thrill-seekers Microglia, the immune cells of the central nervous system, differ in male and female mice. MDC researchers report on the sex-specific features in Cell Reports. Their findings could change how we treat neurological diseases. Press Release No. 34 December 20, 2017 Berlin The dark side of treating cancer with drugs What are the consequences if a cellular aging-like program is acutely activated in tumor cells? And what role does the stem cell program play in it? Press Release No. 26 November 15, 2017 Berlin Gut bacteria are sensitive to salt Common salt reduces the number of certain lactic acid bacteria in the gut of mice and humans according to a study published in Nature by Berlin’s Max Delbrück Center and Charité. This has an impact on immune cells which are partly responsible for autoimmune diseases and hypertension. Probiotics ameliorate the symptoms of disease in mice. Press Release No. 5 January 25, 2016 Berlin Hacking the programs of cancer stem cells All of the cells in a tumor are the offspring of a single, aberrant cell, but they are not all alike. Only a few retain the capacity of the original cell to create an entire tumor. Such cancer stem cells can migrate to other tissues and become fatal metastases. To fully cure a patient’s cancer, it is crucial to find and eliminate all of these cells because any that escape can regenerate the tumor and trigger its spread through the body. Press Release No. 27 November 04, 2015 Berlin Uptake mechanisms of cytostatics discovered How does a cytostatic like cisplatin or carboplatin actually get into the cell? Scientists at the MaxDelbrück Center for Molecular Medicine in the Helmholtz Association (MDC) and the Leibniz-Institut für Molekulare Pharmakologie (FMP) in Berlin, in cooperation with a Dutch group, have now succeeded in showing that the volume-regulated anion channel VRAC is 50 % responsible for active substance uptake. If one of the VRAC subunits LRRC8A or LRRC8D is down-regulated, cells take up considerably less of the anti-cancer drug. In addition to this finding, programmed cell death or apoptosis is also significantly disturbed when LRRC8A is missing. The researchers have thus identified a potential cause for therapy resistance.